BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement.
BioMarin Pharmaceutical Inc. has reiterated its strong financial outlook initially shared at its Investor Day, assuring stakeholders of robust growth prospects. The company expects to hit $4 billion in revenues by 2027, with Non-GAAP Operating Margins reaching 40% in 2026 and increasing thereafter. Additionally, they forecast over $1.25 billion in annual operating cash flow starting in 2027 and a mid-teen revenue growth rate annually through 2034. Treatments for skeletal conditions are also projected to become a significant revenue stream, surpassing $5 billion over time.
Learn more about BMRN stock on TipRanks’ Stock Analysis page.
